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               Introduction 
          
    INTRODUCTION
We stand on the brink of an era in which millions of people are likely to be safer from 
some of the most terrifying and maiming diseases. But, some new and previously unknown 
diseases continue to  emerge,  which are often labelled as ‘re-emerging diseases’.  These, 
amount to a crisis that is a challenge for the public health system in many parts of the world 
86.
Viral  haemorrhagic  fevers  are  becoming  increasingly  common  in  the  tropics  and 
subtropics.  Dengue  fever  is  currently  the  most  important  arthropod  borne  viral  disease 
because  of  its  widespread  distribution  in  more  than  100  countries  and  its  potential  for 
extensive  outbreaks of  life-threatening  disease.   Two-fifths  of  world’s  population  or  2500 
million people are now at risk for dengue and every year approximately 50 million new cases 
occur worldwide.63
Dengue virus was first isolated in India in the year 1945 and is endemic in both urban 
and semi-urban areas. Dengue fever has struck again in India and cases of dengue fever 
(DF)/dengue haemorrhagic fever (DHF) have been reported from various parts of the country 
during the last 4 decades. 86
During the epidemics of dengue, attack rates among susceptibles are 40-90% and an 
estimated 5,00,000 cases of DHF require hospitalization each year, of whom a very large 
proportion are children. 7
Dengue virus, belonging to the genus Flavivirus and Family Flaviviridae, are mosquito 
borne  viruses  and  the  principal  vector,  Aedes aegypti  is  a  day-biting  mosquito  of  public 
importance that breeds in natural or artificial waters.          
Dengue  illnesses  are  caused  by  any one  of  the  four  serologically  related  viruses 
designated as  DENV-1,  DENV-2,DENV-3 and DENV-4.91 Infection  with  any one of  these 
serotypes mostly causes a mild, self-limiting febrile illness (Classical dengue fever), however, 
a few cases develop severe life threatening dengue haemorrhagic fever (DHF) and dengue 
shock syndrome (DSS). 91 
Classical dengue fever is seen 4-6 days after an infective mosquito bite, with sudden 
onset of fever (often biphasic), severe headache, chills, generalized pains in muscles and 
joints, often associated with maculopapular rash. There is leucopenia, relative lymphocytosis, 
thrombocytopenia and haemorrhagic manifestations may occur. 96
DHF and DSS are severe forms of the disease characterized by sudden onset of fever 
and nonspecific signs and symptoms. The critical stage of DHF occurs 24 hrs before to 24 hrs 
after the temperature falls to or below normal. During this time, haemorrhagic manifestations 
usually  occur  and  signs  of  circulatory  failure  may  appear.  Laboratory  tests  show 
thrombocytopenia and evidence of vascular leak syndrome. Hypovolemia, shock and death 
may occur in case of DSS. 96 
Primary  infection  with  one  of  the  four  serotypes  confers  lasting  immunity  to  that 
serotype. Secondary infection with a different serotype is associated with an increased risk of 
DHF. 9
The diagnosis of DF and DHF is made on clinical  and epidemiological grounds. In 
some areas, DHF overlaps with the distribution of other viral haemorrhagic fevers, thereby 
causing a confusion in the diagnosis.
Therefore, serological diagnosis by detection of IgM and IgG antibodies to dengue in 
the serum is essential for monitoring the treatment. Commercial kits are available, which can 
help  in differentiating between primary and secondary dengue infections.  A rapid  dengue 
detection test kit is used for the preliminary diagnosis. ELISA tests are very useful in dengue 
serology. They detect IgM and IgG in the serum and thus are able to distinguish primary and 
secondary infection. 
Since the occurrence of dengue infections and complications like DHF and DSS are 
increasing, this study was conducted to  study the incidence of
dengue infections, to evaluate the seropositivity and to determine the serotype of dengue 
virus in a tertiary care setup, thereby to create awareness about the preventive measures to 
be taken by the general public and the health care system, and to improve our infrastructure 
for diagnosing and treating dengue infections.
       
       Review of    
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REVIEW OF LITERATURE
HISTORY
Dr. Benjamin Rush’s description of a Philadelphia epidemic in 1780 was the earliest 
description of dengue, the break-bone fever. Subsequently, sporadic outbreaks were reported 
throughout the tropics and subtropics.93
Although dengue fever had been described in the 18th century, the virus was isolated 
only during World War II.93
Clinical  description of  dengue complicated by hemorrhages, shock and death were 
reported in outbreaks in Australia in 1897, Greece in 1928 and in Formosa in 1931. Mosquito 
borne transmission of  infection by  Aedes aegypti was demonstrated in 1903 and its viral 
etiology in 1906. Sabin isolated the virus in 1944 and established the existence of dengue 
viral serotypes.75
Between 1944 and 1956 it was shown that four distinct viruses, designated dengue 
virus types 1-4 were responsible for the same clinical syndrome. In 1956, a severe form of the 
disease,  dengue  hemorrhagic  fever/dengue  shock  syndrome  were  described  for  the  first 
time.93
After World War II, the start of a pandemic with intensified transmission of multiple viral 
serotypes began in Southeast Asia, leading to outbreaks of dengue hemorrhagic fever.75
In the last 25 years, a similar pattern of intensified viral transmission and increased 
dengue hemorrhagic fever incidents has been established in south west Asia, the Americas 
and  Oceanic,  fueled  by  secular  changes  toward  urbanization,  population  growth  and 
mobility.75
The Indian encounter with dengue and dengue hemorrhagic fever is interesting and 
intriguing.  The  first  major  epidemic  illness  compatible  clinically  with  dengue  occurred  in 
Madras in 1780 with later spread to all over the country. The dengue virus was first isolated in 
Japan in 1944, but the one isolated in Calcutta in 1944 from the blood of US soldiers was 
considered as a first report for a longtime7.   The epidemics from India include those from 
Calcutta(1963),  Vishakapattanam(1964),  West  Bengal(1968),  Ajmir(1969),  Kanpur  (1969), 
Delhi (1970), Rajasthan (1985) and Delhi in 1996.  102,44
Dengue/ DHF is widely prevalent in India, and all  the 4 serotypes are found in the 
country. It is reported from 15 states/ Union Territories since 1996. In Southern India, the 
disease has been reported in TamilNadu, Karnataka, Andhra Pradesh and Kerala. 67
ETIOLOGY
Dengue  viruses  are  arboviruses  belonging  to  the  Genus Flavivirus and  Family 
Flaviviridae.
CLASSIFICATION
Dengue fever is caused by four antigenically related but distinct viruses (serotypes 1 to 
4) distinguished by neutralization tests.88 Infection with Serotype 1 followed by Serotype 2 is 
more dangerous than Serotype 4 followed by Serotype 2.25 At the genomic level, strains of 
dengue  viruses  belonging  to  same  serotype  are  >90%  homologous  whereas  homology 
across serotypes is approximately 65%. Nucleotide sequencing of the ‘E gene’ has provided a 
means of classifying unique genotypes of each dengue virus serotype.93
Distinct genotypes have evolved in different geographic regions, and genotyping thus 
provides a means of determining the origin and spread of epidemics.93
Genotypic classification of dengue viruses93
Serotype Genotype                       Distribution
    1 I 
II              
III
• Thailand, Indonesia, Malaysia,Pacific Islands 
• Thailand, arribean, Africa,Pacific Islands     
• Thailand,Philippines(Includes Prototype 
Hawaii)
      2 I
II
III
IV
V
VI
• Thailand,Burma,Malaysia,Vietnam,Caribbean 
(includes prototype New Guinea C)
• Srilanka, Seychelles
• Africa
• Africa
• Americas
• Pacific Islands
      3 I
II
III
IV
• Indonesia, Malaysia,Pacific Islands
• Thailand,  Malaysia,  Indonesia,  Burma, 
Vietnam, Philipines(includes prototype H87)
• Carribean, Pacific Islands
• Thailand
      4 I • Philippines,Southeast  Asia,Africa,  America, 
Pacific Islands (includes prototype H241).
MORPHOLOGY
Dengue virus particles are 40 to 50 nm in diameter and have a spherical nucleocapsid 
surrounded  by  a  lipid  bilayer  envelope  with  small  surface  projections  representing  E-
glycoprotein dimers anchored to virus membrane. The lipid envelope is covered densely with 
surface projections comprising 180 copies of the membrane and 180 copies of the envelope 
glycoproteins.39                                                
       
Colour Plate:1; Structure of Dengue virus.
GENOMIC STRUCTURE:
The genome is a single stranded RNA containing approximately 11,000 nucleotides, 
composed  of  short  5’  noncoding  region,  a  single  long  open frame containing  more  than 
10,000 nucleotides and the 3’noncoding terminus.
The long open reading frame encodes three structural proteins at the 5’end which are the capsid 
(C),  premembrane  (preM)  and  envelope  (E)  proteins.  These  are  followed  down  stream by 7non-
structural (NS) proteins in the sequence NS1, NS2a-NS2b-NS3-NS4a-NS4b-NS5. 93
The structural proteins are included in the mature virion, whereas the NS proteins play various 
roles in virus replication and polypeptide processing.
The E proteins are organized as dimers, paired horizontally head to tail, on the virion 
surface.  The  E  protein  exhibits  important  biologic  properties  including  viral  cellular 
attachment, endosomal membrane fusion and the display of sites mediating hemagglutination 
and viral neutralization. 27
OTHER NAMES
Break-bone fever 93,Saddle back (biphasic) fever93
RISK FACTORS FOR DENGUE HEMORRHAGIC FEVER
The risk factors for dengue hemorrhagic fever are:7
o Infestation with Aedes mosquito
o Hot and humid climates enhancing mosquito breeding.
o Mosquito density 
o Presence of all four serotypes of dengue virus with   secondary infection in the 
host.
o Water storage pattern in the houses & Population density
o Larger movement of people towards urban areas. 
EPIDEMIOLOGY
Dengue virus occurs worldwide in tropical region, their distribution determined by the 
presence of the principal mosquito vector, Aedes aegypti. In tropical areas the vector is alive 
year-round and dengue occurs throughout the year with increased transmission during rainy 
season.  This  is  due  to  higher  mean  temperatures  and  the  attendant  shorter  extrinsic 
incubation  period  (the  interval  between feeding  on  an  infectious  blood  and the  ability  to 
transmit on refeeding ) in the vector and to higher humidity and enhanced survival of adult 
mosquitoes93
In temperate zones the transmission is limited to summer months. The distribution and 
abundance of the vector are now more restricted due to improved sanitation and use of piped 
water, but the potential exists for introduction and spread of the virus in temperate areas.93
It is estimated that over 2.5 billion people inhabiting the tropical areas are at risk of 
dengue infection.14
Dengue infections are most prevalent in Southeast Asia where all four serotypes are 
continuously present. In recent years, the Indian sub continent, southern China and Taiwan 
have experienced epidemics. 56
In  areas  of  Southeast  Asia  with  hyper  endemic  infection,  the  annual  incidence  of 
infection is 10 to 20%, and most children have experienced at least one dengue infection by 
age of 7 years.18  
The immunity acquired after infection with one serotype confers full (probably lifelong) 
protection against re-infection with that serotype, but predisposes to more severe disease 
(DHF) on sequential infection with another dengue infection. 93
The intensification of dengue transmission in tropical cities where growing population 
live under crowded conditions can be understood in view of the close relationship of  Aedes 
aegypti to humans.77
After the female mosquito feeds on a viraemic person, viral replication in the mosquito 
over one to two weeks (extrinsic incubation period) occurs before it can transmit the virus on 
subsequent  feeding attempts.  Feeding  attempts  may occur  several  times a  day over  the 
insects’ lifetime of one to four weeks. Adult mosquito shelter indoors and bite during one to 
two hour intervals in the morning and later afternoon. In areas with endemic transmission, one 
of every twenty hours may contain an infected mosquito. 41
The  dissemination  of  dengue  virus  by  viremic  travelers  have  been  facilitated  by 
increased mobility of the people living within endemic areas and internationally by burgeoning 
air travel. 29
The 1996 epidemic in India was mainly due to dengue type 2 virus while the 2003 
epidemic appears to be mainly type3 virus.7
INACTIVATION BY PHYSICAL AND CHEMICAL AGENTS:
Dengue viruses are rapidly inactivated by ionic and nonionic detergents, trypsin, UV 
light, gamma–irradiation, formaldehyde, beta-propiolactone and most disinfectants including 
chlorine, iodine, phenol and alcohol. 93
The  viruses  are  optimally  stable  at  temperatures  below  -70˚C  and  are  rapidly 
inactivated in blood and other liquids within 30 minutes at 50˚C. Dengue viruses are most 
stable at pH 8.4 -8.8 and are rapidly degraded at lower pH. Sensitivity to acid, bile, lipases 
and proteases in the gastrointestinal tract generally precludes infection by the oral route. 93
VECTOR                                                                                 
    Colour Plate:2; 
Aedes aegypti
The vector for dengue virus is Aedes mosquito, which is not affected by the disease, 
although an infected mosquito may infect others. 57
Aedes mosquitoes are easily distinguished by white stripes on a black body, therefore 
referred to as “Tiger mosquitoes”. Aedes aegypti is widely distributed in India. 68
Of  the  three  Aedes  mosquitoes,  ie,  Aedes  aegypti,  Aedes  albopictus and  Aedes 
vittatus, that are commonly collected in TamilNadu,  Aedes aegypti is found to be the most 
prevalent species. 92
Dengue fever  Antigens have been detected in Aedes aegypti mosquito  on several 
occassions  including  certain  rural  areas  and  Aedes  aegypti has  been  proved  to  be  the 
primary vector of dengue. 100
Feeding attempts may occur several times a day over the insects’ lifetime of one to 
four weeks. Adult mosquito shelters indoors and bite during one to two hour intervals in the 
morning and later afternoon.  In areas with endemic transmission, one of every twenty hours 
may contain an infected mosquito. 41
Vertical transmission of DV has also been shown in Aedes aegypti which reveals that 
the virus may be maintained in mosquito even during inter-epidemic periods. 94
TRANSMISSION
Dengue viruses are transmitted to humans through the bites of infective female Aedes 
mosquito.10
 The period of viraemia during which humans are infectious for blood feeding adult 
female  vectors  is  3  to  5  days.   Humans  may  sustain  high  viraemias  with  one  report 
documenting a level of 8.3 log10 units per ml.93
After blood feeding, an extrinsic incubation period of 10 to 14 days must elapse before 
Aedes aegypti can transmit the virus upon refeeding.In rural areas and in some parts of the 
world Aedes albopictus plays a secondary role in inter-human transmission of dengue.28
Infected  female  mosquitoes  may  also  transmit  the  virus  to  their  offsprings  by 
transovarian (via the eggs) transmission, but the role of this in sustaining transmission of virus 
to humans has not yet been delineated.10 Humans are the main amplifying hosts of the virus, 
although studies have shown that in some parts of the world, monkeys may become infected 
and perhaps serve as a source of virus for uninfected mosquitoes.10
Epidemics of dengue peak in September to January period when an  Aedes aegypti  
larval  house  index  of  more  than  40%  is  recorded.  86   Infections  can  be  transmitted  by 
accidental needle stick injury too. Therefore the high incidence of infection in endemic areas 
suggests the possibility that, transfusion associated cases could occur. 76
PATHOGENESIS AND IMMUNOLOGICAL REACTION
Most dengue virus infections are subclinical.  Self-limited dengue fever  is  the usual 
outcome of infection but an immuno-pathogenic response in some patients, usually in the 
setting of heterologous immunity, produces a syndrome of dengue hemorrhagic fever. 24
After an infectious mosquito bite, the virus replicates in local lymph nodes and within 2 
to 3 days disseminates via the blood to various tissues. Virus circulates in the blood typically 
for 5 days in infected monocytes / macrophages, to a lesser extent and to lesser degree in B 
cells and T cells.  It also replicates in skin, reactive spleen lymphoid cells, and macrophages. 
106
Viral antigen can be demonstrated more widely in liver kupffer cells, renal tubular cells and 
alveolar macrophages and endothelia. The malaise and flu-like symptoms that typify dengue probably 
reflect patients’ cytokine response. However myalgia, a cardinal feature of the illness may also indicate 
pathological changes in muscle typified by a moderate perivascular mononuclear infiltrate with lipid 
accumulation. 51
Musculoskeletal pain (break-bone fever) could reflect viral infection of bone marrow 
elements, including mobile macrophages and dendritic cells (CD11b/CD18) and relatively non 
motile adventitial reticular cells.31
Histopathologic examination of skin from patients with rash discloses a minor degree 
of lymphocytic dermal vasculitis and variably, viral antigen. Elevated hepatic transaminase 
concentration  have  been  reported  in  most  cases  of  dengue  with  the  aspartate 
aminotransferase (AST) level initially higher than that of alanine aminotransferase (ALT) and 
levels higher in DHF, compared with dengue fever. 43,34
Shock  in dengue shock syndrome occurs after the sudden extravasation of plasma 
into  extravascular  sites  including  pleural  and  abdominal  cavities,  usually  with  the 
defervescence of fever 55,22.The extensive increase in vascular permeability is associated with 
immune activation, as manifested by increased levels of  plasma soluble Tumour necrosis 
factor receptor (sTNFR), Interlukin (IL)-8, Interferon(IF) gamma and other mediators and local 
endothelial production of IL-8, RANTES (Regulated on activation, normal T expressed and 
secreted)with  apoptotic  endothelial  cell  death.  79 In  addition,  immune  complex  formation 
activates  the  complement  system,  with  increase  in  C3a  and  C5a  levels  of  IL-6  and 
intercellular adhesion molecule -1 are depressed in parallel with hypoalbuminemia and the 
general loss of serum proteins. Reduced cardiac output may contribute further to shock. 33
The hemorrhagic diathesis which is not well understood might be due to a combination 
of cytokine action and vascular injury, viral antibodies binding to patients or cross reacting 
with plasminogen and other clotting factors, reduced platelet function and survival, and a mild 
consumptive coagulopathy.38
Increased frequency of dengue hemorrhagic fever in secondary dengue viral infection 
has suggested a role for heterologous antibodies in enhancing viral uptake and replication in 
Fc receptor- bearing cells (antibody mediated immune enhancement).  23 Increased levels of 
the TNF alpha, soluble CD8 and soluble IL-2 are higher in patients with dengue hemorrhagic 
fever than in dengue fever, which indicates an activation of cross reactive memory of CD4 
and CD8 T- cells in response to a second infection. 57
The resulting production of IL-2, interferon gamma and other lymphokines is reinforced 
by increased abundance of infected target cells resulting from interferon gamma mediated up-
regulation of FC receptors and flaviviral induced expression of MHC type I and II molecules 
that further activate T-lymphocytes. 59
Activated infected monocytes and endothelia produce and release with their lysis TNF 
alpha,  IL-1,  Platelet  activating factor(PAF),  IL-8 and RANTES, which act in  synergy,  with 
lymphokines,  histamine and viral  immune complex induced C3a and C5a to  produce the 
temporary vascular endothelial dysfunction that leads to plasma leakage. 
Illness after infection with 2 serotypes ( i.e., a third bout of dengue) occurs infrequently 
and illness after three infections virtually never. Repeated episodes of dengue hemorrhagic 
fever  have  been  recognized  rarely,  presumably  because  immune  factors  that  promote 
immunopathologic responses are outweighed by immune responses that clear the infections. 
75
ANTIBODY RESPONSE
Colour plate:3; (Sequence of events during dengue infections 
following the bite of infected mosquito)6
Anti-dengue virus IgM antibody is produced transiently during primary and secondary 
infections.In patients with primary dengue virus infections , IgM antibodies develop rapidly 
and are detectable on days 3 to 5 of illness in half of the hospitalized patients. Studies of the 
dynamic antibody response showed that anti-dengue virus IgM levels peak at about 2 weeks 
postinfection and then decline to undetectable levels over 2 to 3 months . Anti-dengue virus 
IgG appears shortly afterwards  20. In contrast to primary infection, secondary infection with 
dengue virus results in the earlier appearance of high titres of cross-reactive IgG antibodies 
before or simultaneously with the IgM responses. 105
Antibodies produced during dengue infection provides short lived protection against 
infection with a heterologous serotype of dengue virus. Neutralizing antibody levels correlate 
with protection against dengue virus. The presence of measurable levels of dengue antibody 
is generally protective, with the exception of low levels of cross-reacting antibodies induced 
by a virus of different serotype than the infecting type. In this situation, the antibody can 
conceivably enhance virus replication and the severity of disease manifestations (according to 
the immune enhancement theory of dengue pathogenesis). 9
Retrospective  studies  have  determined  the  presence  of  neutralizing  anti-dengue 
antibodies in samples of serum from persons affected 40 or more years previously. 65,52,89,19.
Acute primary dengue virus infection is defined as an IgM positive and IgG negative 
result, and acute secondary dengue virus infection is defined as an IgM  and IgG positive or 
IgM negative and IgG positive result. 87
Serological tests for the identification of dengue infection rely on the detection of IgM 
antibodies during the acute phase of infection, either a fourfold rise in antibody titre in paired 
serum collections, or a single serum with a positive result in an IgM antibody capture ELISA. 
105,21
CLINICAL FEATURES
Classical dengue fever is an acute febrile disease with headaches, musculoskeletal 
pains and rash, but the severity of illness and clinical manifestations vary with age. 
Infection is often asymptomatic or nonspecific, consisting of fever, malaise pharyngeal 
infection, upper respiratory symptoms and rash, particularly in children. 13
In severe illness after incubation period of four to seven days, fever often with chills, 
severe frontal headache and retro orbital pain develops abruptly with a rapid progression to 
prostration, severe musculoskeletal sand lumbar back pain and abdominal tenderness. 
Anorexia,  nausea,  vomiting,  hyperaesthesia  of  skin  and  dysgeusia  are  common 
complaints. Initially the skin appears flushed, but in three to four days and with the lysis of 
fever an indistinct macular and sometimes scarlatiform rash develops sparing the palms and 
soles. As the rash fades or desquamates, localized clusters of petechiae on the extensor 
surfaces of limbs may remain. 75
A  second  episode  of  fever  and  symptoms  may  ensue  (“saddle  back”  pattern). 
Recovery may be followed by a prolonged period of listlessness, easy fatiguability, and even 
depression.  Minor  bleeding  from mucosal  surfaces is  not  uncommon and gastrointestinal 
hemorrhage and hemoptysis  can occur.  Hepatitis  can also  frequently  complicate  dengue 
fever. 95
The clinical features of DHF-DSS are hemorrhagic phenomena and hypovolemic shock 
caused by increased vascular permeability and plasma leakage.  With the defervesence of 
fever 2 to 7 days later, reduced perfusions and early signs of shock are manifested by central 
cyanosis, restlessness, diaphoresis and cool clammy skin and extremities. Abdominal pain is 
the common complaint.  In benign cases, BP and pulse may be maintained, but a rapid and 
weak pulse, narrowing of pulse pressure to less than 20 mm Hg and in most extreme cases 
an unobtainable blood pressure establish the shock syndrome. 75
The  platelet  count  declines  and  petechiae  appear  in  wide  spread  distribution  with 
ecchymoses. Bleeding occurs at mucosal surfaces from gastrointestinal tract and at many 
puncture sites. Liver is enlarged in up to 75% of cases. Pleural effusion can be detected in 
more  than  80%  of  cases,  which  in  combination  with  elevated  hematocrit  and 
hypoalbuminemia , reflects hemo-concentration. 75
The presence of pleural and peritoneal effusions is associated with severe disease. 
Acute respiratory distress syndrome may develop with capillary alveolar leakage. In untreated 
patients, hypoperfusion complicated by myocardial dysfunction and reduced ejection fraction 
results in metabolic acidosis and organ failure. 75
The unusual manifestations of dengue fever are dengue myocarditis, encephalopathy, 
encephalitis, intracranial bleed, acute fulminant hepatic failure, persistant thrombocytopenia.11
LABORATORY DIAGNOSIS:
Lab diagnosis of Dengue infection can be made by the detection of specific virus, viral 
antigen, genomic sequence and / or antibodies. 17,20,21,97. At present, the three basic methods 
used  by  most  laboratories  for  the  diagnosis  of  dengue  infections  are  viral  isolation  and 
characterization,  detection  of  the  genomic  sequence  by  a  nucleic  acid  amplification 
technology assay, and detection of dengue virus-specific antibodies. 105
Other  common  laboratory  findings  include  pancytopenia,  neutropenia,  increased 
hemoconcentration, thrombocytopenia and prolonged bleeding time. 99
VIRUS ISOLATION AND CHARACTERISATION
For virus detection, virus isolation by cell  culture and from mosquitoes remains the 
“gold  standard”,  although  it  has  gradually  been  replaced  by  the  Reverse  Transcriptase 
Polymerase Chain Reaction (RT-PCR) method for rapid diagnosis. The isolation of viruses 
from clinical samples can be conveniently carried out with cultured mosquito cells, such as: 
AP-61, Tra-284, C6/36, AP64, CLA-1 cell lines or mammalian cells, such as: LLCMK2, Vero, 
BHK21 cell lines.20
Because of its higher sensitivity, the mosquito inoculation technique is still the method 
of choice for attempting dengue virus isolation from deceased patients with fatal cases or 
patients with severe haemorrhagic disease.  45,78.  Aedes albopictus  16,78  and  Toxorhynchites 
spendens.  104 have been shown to  be useful  for  dengue virus recovery.  At  present,  virus 
isolation with  the C6/36 cell  line with  acute phase serum or  plasma from patients  is  the 
method of choice for routine dengue virus isolation.
Both  cytopathic  effects  (CPE)  (rounding,  refractility  and cell  sloughing)  and plaque 
formation are observed in these cells.  Growth in cell  culture consists  of  a rapid adoption 
phase followed by an eclipse phase of approximately 10-12 hr, after which infectious virus 
first appears and enters a log phase of replication lasting 18-24 hrs. 93
MOLECULAR DIAGNOSIS
The  field  of  molecular  diagnosis  has  changed  significantly  over  the  past  decade, 
leading to assays that are much more reliable for the detection and characterization of various 
pathogens. The Polymerase Chain Reaction(PCR) can be used to amplify and detect RNA 
viruses  by  using  the  enzyme  reverse  transcriptase(RT).2 Various  RT-PCR  protocols  for 
dengue virus have been identified 20,25,46. The two-step nested RT-PCR and single-step nested 
RT-PCR for detection and typing of dengue viruses are well known. 46
These  assays  use  the  dengue  virus  core  to  premembrane  regions  as  the  target 
sequence  for  dengue  virus  detection.  They  have  the  advantage  of  detecting  and 
differentiating the four dengue virus serotypes by analyzing the unique sizes of the amplicons 
in the agarose gel. 72
More recently, the fully automatic real-time PCR assays have been used more widely 
instead of the conventional RT-PCR methods for detection of dengue virus in acute-phase 
serum  samples  due  to  its  advantages  like-  rapidity,  the  ability  to  provide  quantitative 
measurements, a lower contamination rate, a higher sensitivity, a higher specificity, and easy 
standardization. 4,47,70,37
Therefore, real-time PCR has gradually replaced the conventional PCR as the new 
gold  standard  for  the  rapid  diagnosis  of  dengue virus  infections  with  acute-phase serum 
samples. 72
Other  variations  on  amplification  techniques,  such  as  NASBA,  are  becoming 
increasingly popular owing to their relative simplicity and the availability of standardized kits. 
97
SEROLOGICAL DIAGNOSIS    
Among the viral infections that can be diagnosed by serology, dengue virus infection is 
the most challenging due to its cross-reactivity to homologous and heterologous  flavivirus 
antigens. However, great advances in analyzing the complicated viral antigens and antibody 
responses  have  recently  been made  by the  development  of  various  methods that  target 
different  structural  and non-structural  proteins for  sero-diagnosis  and sero-epidemiological 
studies of dengue virus infection.  72
ANTIGEN DETECTION
Recent  studies  have  shown  that  ELISA  and  Dot-blot  assays  directed  to  the  E/M 
antigen and the NS1 antigens in the form of an immune complex could be detected in the 
acute  phase  sera  of  both  patients  with  primary  dengue  virus  infection  and  patients  with 
secondary infection. 37
The  Flavivirus NS1  is  a  46-50  Kilodalton  glycoprotein  which  is  expressed  in  both 
membrane-associated (mNS1) and secreted (sNS1) forms and possesses both group-specific 
and type-specific  determinants.  The procedure of  capture ELISA has been developed for 
detection of flavivirus NS1 in patient’s sera. 69
ANTIBODY DETECTION
Several methods have been described for the serological detection of dengue virus-
specific antibodies, including ;
• Haemagglutination inhibition (HI) test. 8
• Neutralization test. 80
• Indirect immunofluorescent-antibody test.98
• Enzyme-linked immunosorbent assay ( ELISA)3
• Complement fixation test.15
• Dot blotting 5
• Western blotting 41
• Rapid immunochromatography test 72
Among these, capture IgM and/or IgG ELISA, and the HI test are the most commonly 
used serological techniques for the routine diagnosis of dengue virus infections, as they are 
simple and allow large number of samples to be tested. 97
IgM and IgG ELISA have replaced the HAI assay because it has the potential to be 
automated and thus can accommodate a large number of samples. In addition, no processing 
of the serum is required and only a few microlitres of the sample are needed  21. Antigens 
prepared  in  mouse  brain  or  in  tissue  culture  can  be  used.  Several  formats  of 
immunoenzymatic assays for the detection of anti-arbovirus antibody have been described, 
including indirect , capture IgG , the inhibition method, and double antibody sandwich ELISA. 
64,53
The presence of  IgM antibodies to  dengue virus in  the absence of  IgG antibodies 
indicates a primary infection, whereas when IgG antibody titres are higher than those of IgM, 
the presence of a secondary dengue infection is established. 10
DENGUE IgM & IgG CAPTURE ELISA
Serum  IgM/IgG  antibodies,  when  present,  combine  with  Anti-human  IgM/IgG 
antibodies attached to the polystyrene surface of the microtitre plate. A concentrated pool of 
dengue  1-4  antigens  is  diluted  to  the  correct  working  volume,  with  antigen  diluent.  The 
antigens are produced using an insect cell expression system and immunopurified utilizing a 
specific  monoclonal  antibody.  An equal  volume of  the Horse Raddish Peroxidase (HRP)-
conjugated monoclonal antibody is added to the diluted antigen, which allows the formation of 
Antigen-MAb   (Monoclonal  Antibodies)  complexes.  Residual  serum  is  removed  from  the 
assay plate  by  washing  and  complexed  antigen-MAb  is  added  to  the  assay plate.  After 
incubation,  the  microwells  are  washed  and  a  colourless  substrate  system, 
tetramethylbenzidine/ hydrogen peroxide (TMB/ H2O2) is added.
The substrate is then hydrolysed by the enzyme and the chromogen changes to a blue 
colour. After stopping the reaction with acid, the TMB becomes yellow. Colour development is 
indicative of the presence of anti-dengue antibodies in the test sample. 
RAPID DIAGNOSTIC TESTS
Lateral flow tests for dengue antibodies
Lateral  flow tests for antibodies to dengue provide the same information as ELISA. 
Tests  using  recombinant  viral  envelope  glycoproteins  of  dengue  viruses  1,  2,  3  and  4, 
respectively,  are being widely available as commercial  kits.  Although lateral  flow tests for 
dengue may have low sensitivity than ELISAs, they are true rapid tests and have several 
other advantages like,  ease of  performance,  speed,  high stability with  easy differentiation 
between primary and secondary infection using a single dilution of serum.
In Dengue Duo Cassette Rapid test by lateral flow assay, IgM & IgG are determined 
here simultaneously using a single  addition of  serum, plasma or  whole blood.  Therefore, 
differentiation  between  primary  and  secondary  infection  can  be  made  through  single 
application  of  sample  rather  than  a  series  of  dilutions  as  needed  in  Haemagglutination 
Inhibition (HAI) assay.
ANIMAL INOCULATION
All  four  dengue  viruses  have  been  successfully  isolated  in  African  green  monkey 
kidney (Vero)cells  or  1-3  days  old  baby mice  using  a  soup  prepared  from  Ae.  Aegypti. 
Suckling mice are important as it is generally not possible to detect the virus in other animal 
host body (eg. Mosquitoes, ticks) when in low quantity. Mice are inoculated intracranially with 
classified suspensions of clinical specimens or macerated arthropod pools or animal tissues. 
TREATMENT
There is no specific treatment for DF. However careful clinical management frequently 
saves the lives of DHF patients. With appropriate intensive supportive therapy, mortality may 
be reduced to < 1%. Maintenance of the circulating fluid volume is the central feature of DHF 
case management.7 
 The management of DF is supportive with bed rest, adequate fluid intake and control 
of fever and pain with antipyretics and analgesics. For the more severe manifestation of DV 
infection, appropriate management requires early recognition and rapid IV fluid replacement.35 
The hematocrit should be measured frequently.93 In severe cases blood transfusions may be 
required.
On average, DHF case fatality rates are about 5%.103 Case fatality rates can be as high 
as 20-40% in DHF/DSS, but can be reduced with early diagnosis, proper case management 
and using fluid replacement therapy. 
DENGUE VACCINE 
There is no vaccine for DENV/ DHF although significant progress has been made in 
developing  both  live  attenuated  vaccine  candidates  and  second-generation  recombinant 
candidate vaccines using infectious clone technology in recent years.96
There are three major concerns in the development of dengue vaccine. Firstly, is the 
possibility  that  it  could  lead  to  antibody-  dependent  enhancement  of  infection  and  thus 
produce DHF/ DSS. Candidate vaccines based on live attenuated viruses should therefore 
contain  all  four  serotypes  to  give  comprehensive  protection  without  adverse  side  effects. 
Another concern is that possibility of virus evolution through genome recombination. The third 
concern  is  that  the  vaccine  may  produce  adverse  reactions,  for  example,  recently  a 
tetravalent live attenuated vaccine was tested in human volunteers and in children, Phase I 
and Phase II trials have shown mildly adverse reactions with monovalent vaccines, but more 
frequent and significantly more severe reactions with the tetravalent vaccine.  58
The present lack of a successful vaccine against the dengue virus, causes prevention 
methods to be approached.
PREVENTION
A multi-sectoral, multifaceted and comprehensive response will be required to meet the 
challenges of  frequently occurring outbreaks.  Disease surveillance, training of  health care 
providers in medical and paramedical schools and strengthening health infrastructure has to 
be  implemented  through  innovative,  client-friendly  approaches  throughout  the  year  on  a 
regular and sustainable basis. 86
The WHO guidelines 103 for prevention of dengue are that all control efforts should be 
directed  against  mosquitoes.  It  is  important  to  take  control  measures  to  eliminate  the 
mosquitoes and their breeding places. Efforts should be intensified before the transmission 
season (during and after the rainy season) and during epidemics.
Aims of the   
             Study
AIMS OF THE STUDY
 To study the incidence of dengue cases among patients with fever in a tertiary care 
hospital.
 To determine the seropositivity of Dengue cases.
 To categorise dengue cases as dengue fever, dengue haemorrhagic fever and dengue 
shock syndrome , according to WHO guidelines.
 To evaluate the proportion of primary and secondary dengue infections.
 To determine the serotype of dengue virus in dengue positive cases in the early febrile 
period.
Materials &   
           Method
s
 MATERIALS AND METHODS
STUDY PERIOD
This Cross-sectional study was done from October 2006 to October 2007.
SAMPLE
Blood samples from 250 patients with clinical  features suggestive of  dengue, were 
included in this study. The samples were collected aseptically and serum was separated by 
centrifugation technique and stored at -70˚C. 
INCLUSION CRITERIA
The clinical basis for diagnosing the patients as having dengue fever was based on 
standard criteria like presentation of febrile illness of  2-7 days duration, with features like 
headache, myalgia, arthralgia, rash, haemorrhagic manifestations and leucopenia. 103, 82
EXCLUSION CRITERIA
Patients with clinical evidence of urinary tract infection, pneumonia, abscess or any 
other apparent cause of fever were excluded. 44
SOURCE OF SAMPLE
The  samples  were  received  from  fever  clinic  and  from  in-patients  with   features 
suggestive of dengue, Madras Medical College and General Hospital, Chennai-3.
ETHICAL CONSIDERATIONS
Written consent to participate in the study was obtained from the  subjects or their 
guardians  after  the  full  explanation  of  the  study  was  provided  to  them.  This  study  was 
reviewed  and  approved  by  Institutional   Ethical  Committee,  Madras  Medical  college  & 
General Hospital,  Chennai-3. All data were handled confidentially and anonymously. 
STATISTICAL ANALYSIS
The proportional data of this cross-sectional study was tested using Pearson’s Chi-
Square ( X2  )analysis test,  Two sample binomial proportion test,  Statistical  analyses were 
carried out using Statistical Package for Social Sciences( SPSS) and Epi-Info softwares.
METHODS
The samples were subjected to  PANBIO Rapid Duo Cassette method, IgMELISA & 
IgG ELISA at Institute of Microbiology, Madras Medical College & General Hospital, Chennai. 
Single-step nested RT- PCR was done for 28 samples at Christian Medical College, Vellore.
1. RAPID DENGUE DUO CASSETTE METHOD  
The cassette contains a square well for addition of buffer solution,  a  circular well for 
serum  sample  and  a  lateral  flow  membrane  with   colloidal  gold   complexes  containing 
recombinant dengue 1-4 antigens and a control.
Principle of the test
          If dengue specific IgM & IgG antibodies are present in the patients sample, they bind to  
Anti-human IgM or IgG antibodies immobilized in 2 lines across the cassette membrane. 
Colloidal gold complexes containing recombinant dengue 1-4 antigens are captured by the 
bound patients’ IgM or IgG to give visible pink lines. A control is included to indicate that the 
assay has been performed correctly.
Procedure
1. 10µl of whole blood, serum or plasma is added to the circular well in the cassette 
using a micropipette.
2. The sample is allowed to absorb entirely into the specimen pad in the circular well.
3. The buffer (Phosphate buffer saline) bottle is held vertically and 1cm  above the 
square well, adjacent to the circular well in the cassette and 2 drops of buffer is 
added.
4.  The result is read exactly 15 min after adding the buffer to the      cassette.
5. Any trace of a pink line in the test area indicates a positive result.
6. Any results read after 15 min should be considered invalid and       repeated.
 Serological sensitivity of the test  - 96.3%
 Serological specificity of the test  - 95% 
Interpretation of results
Interpretation should be based on the combined results of the IgG         and IgM test lines.
                 C-  Control line
                  
                 M- IgM test line       
G- IgG test line
Primary infection
• Pink bands appear in the IgM & control regions
• The  test  is  positive  for  IgM antibodies  and  is  suggestive  of  primary  dengue 
infection.
Secondary infection    
• (1) Pink bands appear in IgM, IgG and control regions. 
                         The test is positive for IgM & IgG antibodies and is suggestive 
     of secondary dengue infection.
• (2) Pink band appears in IgG and control regions.
          The test is positive for IgG antibodies and is suggestive of 
           secondary dengue infection.
          
Negative
• A pink band appears in the control region only.
• No detectable IgG or IgM antibodies to dengue.
Invalid
• No pink band appears in control region.
• The test is invalid.
2.DENGUE ANTIBODY ELISA 
REQUIREMENTS
1. Anti-human IgM / IgG coated microwells (Assay plate)
2. Dengue 1-4 antigens (Recombinant)
3. Wash buffer concentrate-20X concentrate of phosphate buffered saline (PBS) ,pH 
7.2-7.6 with Tween 20 and 0.1% proclin as preservative.
4. Serum diluent-Tris buffered saline with preservatives and additives.
5. Antigen diluent- PBS with preservative and 0.005% gentamycin.
6. Horse Raddish Peroxidase(HRP) conjugated Monoclonal Antibody Tracer
7. Tetramethyl benzidine (TMB)- 3,3’,5,5’-the substrate, tetramethyl   
benzidine, hydrogen peroxide in a citric-acid citrate buffer (pH 3.5-3.8)
8. Positive control serum,Negative control serum, and cut-off calibrator  - Human 
serum with 0.1 % sodium azide and 0.005% gentamycin sulphate.
9. Stop solution-1Mole Phosphoric acid.
DENGUE IgM CAPTURE ELISA
PROCEDURE
Serum predilution
1. The microwells are inserted into the strip holder. 5 microwells are                  required for 
positive control (PC), negative control(NC) and cutt-off       calibrator (CO) in triplicate.
2. The PC,NC & CO & patient samples are diluted using suitable test tubes or microtitre 
plate.
3. 1000 µl or 1ml of serum diluent is added to 10µl of serum and mixed well.
Elisa procedure
1. Antigen is diluted 1/250 using the antigen diluent. ie, 10µl of antigen + 2.5 ml of antigen 
diluent. A volume of 0.5 ml of diluted  antigen is required per strip.
2. Required volume of diluted antigen is mixed with equal volume of  MAb tracer (Horse 
Raddish Peroxidase conjugated Monoclonal antibody tracer) in a test tube and kept at 
room temperature (20- 25˚C) until required.
3. 100µl of diluted patient sample and controls (one positive control, one negative control 
and three cut-off calibrators) are pipetted into their respective microwells of the assay 
plate.
4. The plate is covered and incubated for 1 hour at 37˚C.
5. After incubation , the plate is washed 6 times with diluted wash buffer.
6. The antigen- MAb tracer solution is mixed well and 100µl is transferred to microtitre wells.
7. The plate is covered and incubated for 1 hour at 37˚ C.
8. The plates are washed 6 times with diluted wash buffer after incubation.
9. 100µl  of  TMB(Tetramethylbenzidine)  is  pipetted  into  each  well  and  a  blue  colour 
develops. The plate is incubated for 10 min at room temperature. 
10.At the end of 10min, 100µl of stop solution is pipetted into all wells.              The blue 
colour will change into yellow.
11.The absorbance of each well is read at a wavelength of 450nm with a reference filter of 
600-650nm, using a dual wavelength spectrophotometer.
Calculations
• The cut-off value was determined by calculating the average       absorbance of the 
triplicate of the cut-off calibrator. 
• The index value was calculated by dividing the sample absorbance by the cut-off value.
• Panbio units can be calculated by multiplying the index value by 10.
                  Index value=   Sample absorbance
                                             Cut-off value
                  Panbio units= Index value x 10.
       Test validity:
 Calibrator mean ≥ 1.5 x Negative absorbance.
  Positive control     = 1.1-6.0
         Cut-off
                     
 Negative control < 0.350 
     Interpretation of results
             Index          Panbio units         Results
            <0.9               <9         Negative   
           0.9-1.1             9-11         Equivocal
            >1.1               >11         Positive
Sensitivity of this test is 94.7%, Specificity is 100%.
 
      
3.DENGUE IgG CAPTURE ELISA
 
 PROCEDURE
The dengue IgG ELISA  is set to detect high levels of IgG present in secondary but not 
primary or past dengue infections. All the reagents were brought to room temperature and 
serum pre- dilution done as for dengue IgM capture ELISA.          
  
 Elisa procedure
1. Antigens are reconstituted with antigen reconstitution buffer. 1ml of                reconstitution 
buffer was added to antigen and mixed.
2. Required volume of reconstituted antigen is mixed with an equal           volume of  MAb 
tracer (Horse Raddish Peroxidase conjugated             Monoclonal antibody tracer) in a test 
tube and kept at room temperature until required.
3. Add 100µl of diluted patient sample and controls into their respective microwells of the 
assay plate (anti-human IgG coated microwells).
4. The plate is covered and incubated for 30 min at 37*C.
5. After incubation, the plate is washed 6 times with diluted wash buffer.
6. The antigen- MAb tracer solution is mixed well and 100µl is                transfered to 
microtitre wells.
7. The plate is covered and incubated for 1 hour at 37* C.
8. The plates are washed 6 times with diluted wash buffer after incubation.
9. 100µl of Tetramethylbenzidine is pipetted into each well and                incubated for 10 min 
at room temperature, a blue colour will  develop.
10.At the end of 10min, 100µl of stop solution is pipetted into all wells. The blue colour will 
change into yellow.
11.The absorbance of each well is read at a wavelength of 450nm with a reference filter of 
600-650nm, using a dual wavelength         spectrophotometer.
Calculations
• The cut-off  value  was determined by calculating  the average      absorbance of  the 
triplicate of the cut-off calibrator. 
 
• The index value was calculated by dividing the sample absorbance by the cut-off value.
• Panbio units can be calculated by multiplying the index value by 10.
                  Index value=   Sample absorbance
                                             Cut-off value
                  Panbio units= Index value x 10.
  Test validity:
•    Calibrator mean > Negative absorbance.
•    Positive control     = 1.1-6.0
             Cut-off
•    Negative control < 0.350
             Interpretation of results:
         Index          Panbio units         Results
         <0.9                <9         Negative   
       0.9-1.1             9-11         Equivocal
         >1.1              >11         Positive
   Sensitivity of this test is 85.7% and specificity is 100%.
4. SINGLE STEP NESTED RT-PCR USING NS3 PRIMERS
(i).Viral RNA Extraction. ( Qiagen Viral RNA Extraction kit) 83,1         
Requirements:
1. QIAamp membrane ( Provided in the kit)
2. Wash buffers-1 & 2 (Guanidine hydrochloride buffers, differing by concentration)
3. Elution buffer ( RNase free buffer)
4. Ethanol (96-100%)
5. Carrier RNA
6. Buffer 3 (Guanidine thiocyanate)
7. 1.5ml microcentrifuge tube
8. Microcentrifuge and Vortex equipments
Principle
• The sample is first lysed under highly denaturing conditions     (provided by buffer 3) 
(Guanidine isothiocyanate method) 44   to inactivate RNAses & to ensure isolation of intact 
viral RNA.
• Carrier RNA is added to buffer 3, to improve the binding of viral  RNA to the QIA amp 
membrane.
• Bufffering conditions are then adjusted to provide optimum binding   of the RNA to the 
QIAamp membrane, and the sample is loaded on to the Mini spin column.
• The viral RNA binds to the membrane and contaminants are    efficiently washed away in 
2 steps using 2 different wash buffers- 1 & 2.
• Elution is done to obtain High-quality RNA using a special RNase- free buffer, the elution 
buffer that contains 0.04% sodium azide.
• The purified RNA is free of protein, nucleases and other contaminants and  inhibitors. 
The total procedure time is 20 minutes.
• Determination of viral RNA yield is difficult, because, they are normally less than 1µg and 
therefore difficult to determine photometrically. Therefore, Quantitative RT-PCR is done 
to   determine the viral RNA yield.
  
Viral RNA Extraction Procedure: 
• 560µl of buffer 3 containing carrier RNA was pippeted into a 1.5 ml  microcentrifuge 
tube.
• The  serum  sample  was  added  to  the  tube  and  mixed  by  pulse-   vortexing  for  15 
seconds.
• The mixture was incubated for 10 minutes at room temperature.
• The tube was centrifuged briefly to remove drops from the inside of the lid.
• 560µl of ethanol (96-100%) was added to the sample, and mixed by pulse-vortexing for 
15 secs. After mixing, the tube was briefly centrifuged to remove drops from inside the 
lid.
• 630µl of solution was added to a 2ml collection tube and centrifuged for 1 min at 8000 
rpm. The collection tube was placed in the spin column and the tube containing the 
filtrate was discarded.
• Step 6 was repeated.
• 500µl  of  buffer  1(Guanidine  hydrochloride)  was  added  to  the  Mini  spin  column  & 
centrifuged at 8000 rpm for 1 min. The Mini spin column was placed in a 2ml collection 
tube and the filtrate discarded.
• 500µl of buffer 2 was added, cap closed & centrifuged at full speed, at 14000 rpm for 3 
minutes.
• The QIA amp mini spin column was placed in a 1.5 ml micro-centrifuge tube and the old 
container tube containing filtrate was discarded.
• The QIA amp spin column was opened and 60µl of elution buffer was added (to elute 
the viral RNA from the QIAamp mini spin column) and incubated at room temperature 
for 1 minute.
• After centrifugation at 8000 rpm for 1 minute, the viral RNA is ready for RT-PCR. 
(ii) SINGLE-STEP NESTED RT-PCR
Principle
The single-step nested PCR reaction consists of using two primer sets directed against 
the same target, wherein both sets of primers are added together and an extended PCR is 
performed.35
 Components of PCR
 Oligonucleotides
Oligonucleotides used in this procedure were 17-23 nucleotides in length. They were 
used at a concentration of 10 pmol for 35 cycles of amplification.
 Description of primers
  Prime
r
    
              5’-3’ sequence Nucleotide 
position 
Target 
size(when 
used with 
DV1) 
Length of 
the 
sequence
  DV1 GGRACKTCAGGWTCTCC 4918-4934 - 17
 DSP1 AGTTTCTTTTCCTAAACACCTCG   5067-5045 169bp 23
 DSP2 CCGGYGTGCTCRGCYCTGAT   5279-5260 362bp 20
 DSP3 TTAGAGTYCTTAAGCGTCTCTTG   5174-5152 265bp 23
 DSP4 CCTGGTTGATGACAAAAGTCTTG   5342-5320 426bp 23
Buffer used
1X PCR buffer containing 1.5mM magnesium chloride (MgCl2) was used.
Taq. DNA polymerase
Taq polymerase,derived from  Thermus aquaticus,  was used in  the  reaction,  which 
carries a 3’ to 5’ exonuclease activity. The final concentration of Taq polymerase used was 
0.5U.
Deoxynucleotide Triphosphate(dNTP’s)
dNTP’s was used at a saturating concentrartion of 0.2 mM .
Reverse transcriptase
Commercially available reverse transcriptase (derived from Moloney murine leukemia 
virus -MMLV),  in a concentration of 25U was used for the procedure.
Positive control
Dengue  virus  serotypes  1-4  were  received  from  National  Institute  of  Virology 
(NIV),Pune and cultured in African green monkey kidney cells(Vero). The cytopathic effects of 
rounding and detachment from the surface was seen by fifth day after the passage. This was 
used as the positive control. 
PCR Reaction Mixture
Components Final concentration of 
reagents
Quantity of 
reagents
 PCR buffer MgCl 21.5mM, Tris-HCl 
50mM, KCl 75mM, pH 8.3
10µl
 dNTP 0.2mM 2µl
 Forward Primer 10pM 2µl
 Reverse Primers 10pM 8µl (2x4)
Taq.Polymerase 0.5U 1µl
Reverse transcriptase 25U 1µl
Water 6µl
RNA extract (Template) 20µl
Total volume of each reaction 50µl
SINGLE –STEP NESTED RT-PCR PROCEDURE (Seah et al,1995)82
1. This method was performed in a 50µl volume comprising- sample RNA template, PCR 
buffer  with  1.5mM  MgCl2, DV1  &  DSP  1-4  primers  10pM  each,  25U  of  reverse 
transcriptase , 0.5U of Taq polymerase ,0.2mM dNTP.
2. The mixture was subjected to RT at 50˚C for 15 minutes, followed by an initial 95˚C for 1 
minute, 10 PCR cycles of denaturation  at 95˚C for 0.5 minute ,annealing at 50˚C for 1 
minute between each segment ; and 20-25 PCR cycles of 95˚C for 0.5 minute, 50˚C for 
0.5 minute & 72˚C for 0.5 minute with a ramp temperature of 0.5 minute.
3. Amplification was carried out in Perkin Elmer Gene amp PCR system.
4. 10µl of each PCR product were resolved by electrophoresis in 2% agarose gels in TBE 
buffer (pH-8.0), containing 0.5µL ethidium bromide and viewed under a UV 
transilluminator.
5. To avoid risk of false positives, both positive and negative controls were included in the 
assay.
6. If positive amplification is present, bands will be seen at 169 bp, 362 bp, 265 bp and 426 
bp.
     Results
 RESULTS
Total number of samples tested :  250
• PANBIO Rapid Duo Cassette method, IgM ELISA and IgG ELISA methods were 
done  for  the  samples  at  Institute  of  Microbiology,  Madras  Medical  college  & 
General Hospital, Chennai-3
• Single-step nested RT-PCR was done for 28 samples at Christian    
      Medical College, Vellore.
• Clinical data was collected for all patients.
TABLE-1:
INCIDENCE OF DENGUE FEVER
Total number
of
fever cases
Suspected
Number
Of cases
Dengue
positive
cases
Incidence
10113 250 90 0.88
Incidence rate=90/10113x100=0.88%
(0.72%-1.10%) with 95% confidence interval
     Burden of disease=1 out of 112 patients.
TABLE-2 
           
    SEROPOSITIVITY OF DENGUE
Total no. of 
suspected
Cases
Total no. of 
positive
Cases
Percentage
(%)
250 90 36
Seropositivity = 36% (Range=30-42% ) with 95% Confidence Interval
TABLE- 3 
AGE DISTRIBUTION OF DENGUE CASES (n=90)
Age group Total cases Positive cases Percentage
(%)
0-20yrs 72 31 43.05
21-40yrs 110 51 46.36
>40yrs 68 8 11.76
Age group 21-40yrs was commonly involved in both sexes
Chi Square(X 2 ) test = 14.06; p=0.001 ( Significant)
TABLE-4
SEX DISTRIBUTION OF DENGUE CASES
Sex Total cases Positive cases Percentage
(%)
Males 119 51 42.85
Females 131 39 29.77
Total 250 90
  Two sample Binomial proportion test =2.15; p=0.03. (Significant)
TABLE - 5
 CLINICAL PRESENTATION OF DENGUE (n=90)
S.No Clinical Features Number of 
patients
Percentage
(%)
1. Fever 90    100 
2. Myalgia / Arthralgia 64   71.1
3. Headache 44 48.88
4. Haemorrhagic manifestations 35 38.88
5. Rash 25 27.77
6. Gastro intestinal symptoms 20 22.22
7. Hepatomegaly 15 16.66
8. Retro-orbital pain 12 13.33
Fever was common to all cases. Other than fever, Myalgia / Arthralgia predominated 
the symptoms, followed by Headache.
TABLE- 6
HAEMORRHAGIC MANIFESTATIONS OF DENGUE CASES ( n=35)
    
      Symptoms          Number of  cases Percentage
(%)
Bleeding gums 9 25.71
Petechiae 8 22.85
Haematemesis 5 14.28
Malena 5 14.28
Epistaxis 5 14.28
Vaginal bleeding 2   5.71
Ecchymosis 1   2.85
The common haemorrhagic manifestations seen in dengue patients                   were 
gum bleeding followed by petechiae. 
TABLE- 7 
SEASONAL DISTRIBUTION OF DENGUE  CASES
Month
/
Year
Total number of 
suspected
Cases
Total number
of positive
Cases
Percentage
(%)
Oct’06 17 6 35.29
Nov’06 37 10 28.57
Dec’06 26 9 34.61
Jan’07 17 4 23.52
Feb’07 11 1   9.09
Mar’07 10 1     10
Apr’07 5 0       0
May’07 7 2 28.57
Jun’07 9 1 11.11
Jul’07 16 3 18.75
Aug’07 16 9 56.25
Sep’07 24 13 54.16
Oct’07 55 31 56.36
Total 250 90
Increase in incidence of dengue cases during rainy season is 
clearly seen from this table
TABLE- 8 
THROMBOCYTOPENIA IN DENGUE CASES(n=90)
Platelet count
(lakhs/cu.mm)
Total cases Percentage
(%)
<20,000 27 30
21,000 -40,000 16 17.77
41,000-50,000 8 8.88
50,000-1 lakh 30 33.33
> 1 lakh 9 10
All dengue cases had thrombocytopenia and most cases 
had a platelet count of 50,000-1 lakh/cu.mm.
        TABLE- 9
               
          ANTIBODY RESULTS IN EARLY & LATE FEBRILE PERIOD (n=90)
Duration IgM
ELISA
% IgG
ELISA
% Both
Positive
%
1-5 days
(n=45`)
30 66.66 3 6.66 12 26.66
6-10 days
(n=29)
2 6.89 7 24.13 30 68.96
>10 days
(n=16)
2 12.5 10 62.5 4 0.25
Total % of 
Antibody 
detection
IgM-37.77% IgG-22.22% Both-51.11%
                           
IgM positivity was more in the early febrile period and both IgM & IgG  were 
common in the 6-10 day fever group.
                      X2   square test = 57.69; p = 0.001 (Significant) 
                                                          
TABLE- 10
CATEGORISATION OF DENGUE CASES  (n=90)
Category of dengue No.of cases Percentage
(%)
Dengue fever 45 50
Dengue haemorrhagic 
fever
38 42.22
Dengue shock syndrome 7 7.7
    More number of cases were found in the dengue fever group.
                            
               
      
   
 
TABLE- 11
CLASSIFICATION OF DENGUE BASED ON WHO GUIDELINES103
        
        ( i ) DENGUE FEVER (n=45)
Sl.No.         Signs&Symptoms
    
      No.of  
   Patients
  
 Percentage     
      (%)       
   1 Headache         26      57.77
   2 Retro-orbital pain         12      26.66
   3 Myalgia/Arthralgia         32      71.11
   4 Rash         26      57.77
   5 Haemorrhagic manifestations           9      20.00
   6 Leukopenia         25      55.55
        Myalgia/  Arthralgia   followed  by  headache  &  rash  were  the  common 
manifestations in the dengue fever group.
   ( ii )DENGUE HAEMORRHAGIC FEVER(n=38)
Sl.No
    
         Signs&Symptoms
      
      No.of  
     Patients
  
     Percentage 
           (%)
1 Petechiae,Ecchymosis 9 23.68
2 Bleeding from mucosal sites 7 18.42
3 Hemetemesis/Malena 10 26.31
4 Thrombocytopenia
                           <1 lakh
                           >1 lakh
36
2
94.73
5.26
5 Evidence of plasma
Leakage
( >20% ↑in hematocrit,
Pleural effusion,
Ascites,
Hypoprotenemia)
24 63.15
       Thrombocytopenia was seen more in the dengue haemorrhagic fever group.
   
   
     ( iii ) DENGUE SHOCK SYNDROME (n=7)
Sl.No
     
     Signs&Symptoms     No.of cases
  
  Percentage 
         (%)
   1 Rapid, weak pulse         6       85.71
   2 Narrow pulse pressure         5         60
   3 Hypotension         7       100
   4 Cold, Clammy skin & 
restlessness
        7       100
TABLE- 12
COMPARISION OF CLINICAL FEATURES AND LAB PARAMETERS BETWEEN DF & 
DHF/DSS
Variables DF Positive / %
(n=45)
DHF / DSS
Positive / %(n=45)
Clinical Features
Age group 21-40 yrs 21-40yrs
Sex Males (64.44%) Females (60%)
Haemorrhagic Manifestations 29(64.44%) 36(80%)
Retro-orbital Pain 12(26.66%) 4(8.88%)
Average days of stay in the hospital 4-6 5-11
Platelet transfusions 3 26
Outcome
Deaths - 2
Lab Findings
Elevated SGOT(AST)
(>40U/mL)
16(35%) 31(68.88%)
Elevated SGPT(ALT)
(>35U/mL)
14(35%) 26(57.77%)
Elevated BT/CT 26(57.77%) 41(91.11%)
Thrombocytopenia
(Platelet< 1.5lakhs/cu.mm)
38(84.44%) 43(95.55%)
Hypoproteinemia
(Total protein<6 gms)
- 24(53.33%)
Elevated Haematocrit
( Haematocrit>45%)
- 26(57.77%)
Leukopenia
(<4000/cu.mm)
24(53.33%) 28(62.22%)
                              
TABLE- 13
COMPARISION OF VARIOUS METHODS USED FOR DIAGNOSIS OF DENGUE
Methods Tested Positive Percentage
(  % )
Rapid test 250 86 34.4
IgM ELISA 250 80 32
IgG ELISA 250 66 26.4
Rapid detection method was more sensitive than ELISA 
           for the detection of dengue from clinically suspected cases
TABLE- 14
DENGUE SEROTYPING BY SINGLE-STEP NESTED RT-PCR(n=28)
Antibody status No. of samples 
tested
No. positive
IgM  positive & IgG
Negative
15 Nil
IgM & IgG negative 13 1
   Detection of the viral genome was positive in the antibody negative group
TABLE-15
PRIMERS USED IN SINGLE-STEP NESTED RT-PCR FOR IgM & IgG 
NEGATIVE SAMPLES (n=13)
Primers Number of 
samples tested
Number of samples 
Positive
DSP-1 
(Dengue serotype-1)
13 1
DSP-2 
(Dengue serotype-2)
13 Nil
DSP-3
(Dengue serotype-3)
13 Nil
DSP-4 
(Dengue serotype-4)
13 Nil
Dengue serotype 1 was identified in a case by 
                                Single-Step Nested RT-PCR
                         
TABLE- 16 
                             DETAILS OF SINGLE STEP NESTED RT-PCR 
                                             POSITIVE DENGUE CASE
Age/Sex Fever duration Antibody status Other 
symptoms
19/F 2 days IgM & IgG ELISA 
negative
Headache,
Vomiting.
Platelet-1 lakh
Both antibodies were negative in this patient with 
2 days fever duration.
TABLE- 17
   
CATEGORISATION OF DENGUE INTO PRIMARY AND SECONDARY INFECTIONS 
BASED ON IgM : IgG RATIO61   ( n=90)
IgM : IgG
Ratio
Number of 
cases
Percentag
e
Interpretation
≥1.78 26 28.88 Primary
Dengue Infection
<1.78 64 71.11 Secondary
Dengue infection
The incidence of secondary dengue infection was much 
higher than primary dengue infection in the present study.
        The proportion of primary to secondary dengue was found to be 1:2.5
TABLE- 18
                  
CASE FATALITY IN DENGUE CASES
Total Dengue
Cases
Number of
Deaths
CFR
90 2 2.2%
Range = 1-9% (Based on Odds Ratio )
           Incidence of Mortality = 1 out of 45 dengue cases.
TABLE-  19:
 CLINICAL CLASSIFICATION OF 2 FATAL DENGUE CASES
Case Sex/
Age
Underlying
Conditions
Presentation
of symptoms
 Classif
i
-cation
Hospital
stay
(days)
Cause
of
death
    1 F/21       Nil  Fever, 
Hemetemesis,
Renal failure, 
Peritoneal 
dialysis done  
   DSS      3 Profound 
shock, HF, 
ARF, 
brainstem 
dysfunction,
ICH, Cardio-
Pulmonary 
arrest.
    2 F/22  Antenatal Fever, Pallor, 
Rashes, 
Dyspnea, 
Peripheral 
cyanosis, 
Purpura
   DSS     2 Profound 
shock, 
Cardio-
pulmonary 
arrest.
       HF-Hepatic failure; ARF-Acute renal failure; ICH-Intra cranial haemorrhage
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Discussion
DISCUSSION
Dengue has been increasingly recognized as an emerging infectious disease for the 
last four decades. The global burden of dengue has grown dramatically in recent years. 
The  high  presvalence  of  dengue  cases  at  Chennai  in  the  recent  years,  makes  it 
necessary to evaluate the incidence of dengue and to find out the seropositivity of  dengue 
cases.
Rapid diagnosis of dengue is crucial for proper patient care. As IgM antibody appears 
early during the disease course, its detection is a valuable tool for rapid diagnosis.
This study was done with 250 serum samples from patients with clinical symptoms 
suggestive of dengue.
The incidence of dengue fever in this study, over a period of one year (from October 
2006 to October 2007) was 0.88% (Table-1), among fever cases attending the fever clinic and 
those admitted in our hospital.
The seropositivity  of  dengue cases (Table-2)  in  the  present  study among clinically 
suspected fever cases was 36%.In the study conducted by Khoa TD et al, in 2005 at Vietnam, 
the seropositivity was 53% 34.
A higher distribution of dengue cases in the present study was seen in the  (Table-3) 
21-40 year age group 51( 46.36%), followed by 0-20 age group 31(43.05%) and above 40 
age group 8(11.76%).This was similar to the study conducted by Preeti Bharaj et al in 2008, 
in which the common age group involved was 20-40 years(35.4%) , followed by 0-20 years 
group(20.8%).72 Ekta gupta et al, in 2006, in her work also showed that the maximum number 
of cases in a 3 year study period was seen in the 21-40 year age group. 11
In  this  study,  an  increased  incidence  of  dengue  was  found  among  male  patients 
51(42.85%), as compared to females 39 (29.77%) (Table-4). In the study done by Nadeem 
Sajjad  Raja  et  al  in  2006,  they observed an incidence  of  51.55% in  males  and 48% in 
females58, and in the study by Kurukumbi et al in 200142, it was observed that the incidence 
was 61.5% in males and 38.5% in females.
The predominant symptoms with which the patients presented in the present study 
(Table-5)  were  fever(100%),  myalgia/  arthralgia  (71.1%),  haemorrhagic  manifestations 
(38.88%),  headache  (48.88%),  Rash  (27.77%),gastro-intestinal  symptoms 
(22.22%),hepatomegaly (16.66%) and retro-orbital pain(13.33%).In the study conducted by 
Min-Shen Lee et al in 2005, a one year study  involving 1551 patients in Taiwan, fever was 
the most common symptom (96.1) , followed by myalgia (68.5%), headache (55.4%), skin 
rash (53.7%) and retro-orbital pain (15.8%), which correlated well with the present study 52. In 
a 16 months study by Shahid Ahamed et al in200883, involving 5200 fever cases, they showed 
that  fever  was  the  commonest  symptom  (100%),  followed  by,  myalgia  (67%),  headache 
(54%) and rash (28%).
Haemorrhagic manifestations (Table-6) were seen in 35 cases (38.88%), in the present 
study,  which  included petechiae in  8  cases(22.85%),  bleeding gums in  9  cases(25.71%), 
epistaxis  in  5  cases(  14.28%),  hemetemesis  in  5  cases  (14.28%),  malena  in  5  cases 
(14.28%),  ecchymosis  in  1  case  (2.85%),  and  vaginal  bleeding  in  2  cases  (5.71%). 
Leukopenia was seen in 52 (57.77%) patients(Table-12),  thrombocytopenia (Table-8) with 
platelet  count  of  less than 1 lakh was seen in 81 cases (90%) and more than 1 lakh in 
9(10%)cases. In a study by Shahid Ahmed et al, in 2008, gum bleeding & epistaxis were seen 
in 40%, hemetemesis in 22%, malena in 14%, leucopenia in 73% and thrombocytopenia in 
84% of cases, which closely resembles our values 83. In the study done by Min-Sheng Lee et 
al, in 2005 at Taiwan, they observed that haemorrhagic manifestations were present in 73% 
of patients, with bleeding from skin and mucosal sites of 70.6%, leucopenia sin 55% and 
thrombocytopenia in 78.9% of patients52.
The incidence of dengue is higher following rainfall. True to this, in the present study, a 
clear  cut  increase in  incidence  of  dengue  cases  (Table-7)  was  seen between August  to 
December  when  TamilNadu  receives  rainfall  from  North  East  monsoon.  In  a  Laboratory 
based study on dengue fever surveillance conducted by John Victor et al in 2007, the data on 
monthwise  incidence  of  dengue  in  Tamilnadu  for  the  past  nine  years  revealed  that  the 
number of cases increased from June to December, confirming that the active transmission 
period is during monsoon and post–monsoon period every year31.In a study by Kurukumbi M 
et al, in  2001 done for a period of one year at AIIMS, New Delhi, and it was observed that the 
peak  incidence  of  dengue  infection  occurred  between  September  and  November,  which 
shows results similar to the present study. 42
According to WHO guidelines101  (Table-10 &11), dengue cases in the present study 
were  categorized  into  dengue  fever(DF)  45(50%),  dengue  haemorrhagic  fever(DHF) 
38(42.22%) and dengue shock syndrome(DSS) 7(7.7%). Preeti Bharaj et al, in 2008 in her 
study  in  New  Delhi,  showed  53.84%  cases  with  dengue  fever,  35.89  %  with  dengue 
haemorrhagic fever and 10.25% with dengue shock syndrome, which showed slightly similar 
results to the present study 72.
In the present study, an increased detection of IgM antibody (66.66%) was seen in the 
early febrile period (1-5 days) (Table-9), as compared to the late period (6-10 days) , when 
both  IgM and  IgG antibodies  are  seen  at  higher  levels  (  68.96%).  IgM antibodies  were 
detected in 37.7% of the samples and  IgG in 22.22% and both IgM & IgG were detected in 
51.11% of  patients  in  this  study.  In  the study by Neeraja  et  al  in  2006,  done at  Andhra 
Pradesh, IgG was detected in 40.28% cases, IgM in 3.8% of cases and both IgM & IgG in 
55.9% of cases60 
Elevations  of  hematocrit  to  ≥  20% (Table-12)  were  seen in  more  than half  of  the 
subjects with dengue haemorrhagic fever. Elevated AST levels, elevated bleeding time and 
clotting time and hypoprotenemia were seen more in DHF patients.  In the study done by 
Kalayanarooj et al, in 1997 at Bangkok, elevation of hematocrit and other parameters were 
seen in half of the subjects with DHF 33. 
Platelet transfusions(Table-12) were given for 3 patients with DF, 20 patients with DHF 
and 7 patients with DSS, a total of 29 (32.22%) patients in the present study. In the study 
conducted by Malavige et al, in 2006 at Srilanka, platelet transfusions were needed for 38% 
of  patients  with  severe  thrombocytopenia48. In  Makroo  et  al’s  stuty  in  200747,  platelet 
transfusions were given to  42.6% of patients47. 
In the present study Rapid dengue duo cassette method, IgM ELISA, and IgG ELISA 
were done for 250 samples (Table-13). Rapid test was positive for 86 samples( 34.4%), IgM 
ELISA in 80 samples (32%) and IgG ELISA in 66 samples (26.4%). The detection of dengue 
cases was more by rapid test method when compared to the other two methods in this study. 
In the study by Satish et al., at CMC Vellore in 2003, they also found that the detection of 
dengue was more by Rapid tests than ELISA.80   
Single-step nested RT-PCR was done at CMC, Vellore  for 15 samples (Table-14) in 
the early febrile period which were positive for IgM antibody , but viral genomes could not be 
detected in those samples. RT-PCR was repeated with 13 other samples in the early febrile 
period,  which were negative for  IgM and IgG antibodies, collected from patients clinically 
suspected of  having dengue fever.  Dengue serotype-1 was detected in  one sample  with 
history of fever for two days. This could be due to the fact that , viremia declines soon after 
antibodies  start appearing 10, 6. There is also a possibility that patients reporting to General 
Hospital usually present at the late febrile period since this is a tertiary care hospital, the time 
by which the chances of detection of virus  is very low. Hence, much earlier samples, very 
soon after fever occurs, should be collected and subjected for dengue PCR for detection of 
the viremia and for serotyping studies. 
Dengue serotype 1 was detected in one sample among 13 samples by Single step 
nested RT-PCR in this study(Table-15). In the study by Kukreti et al.,  in 2006 at Delhi,  a 
sudden emergence of dengue virus serotype 1 was observed in the 2006 outbreak 40. 
In the present study, the proportion of primary dengue infections to secondary dengue 
infections was 1:2.5 (Table-17), with primary infections in 28.88% of patients and secondary 
dengue infections in 71.11% of cases .In Malavige et  al’s  study conducted in 2006, they 
observed that 34.3% patients presented with primary dengue  and 65.7% with secondary 
dengue which correlates with the present study48  .Ole Wichmann et al, in 2004 at Humbolt 
university, Berlin, Germany documented 79.5% of secondary infections in his study, which 
was very close to the present study 61.
Case fatality rate seen in the present study was 2.2%(Table-18). This was similar to 
the study conducted by Nazish Butt et al, in 2007, who observed a case fatality rate of 2.88% 
59. The WHO fact sheet 2002 also shows a statistics of 2.5% case fatality rate each year 
among dengue cases, which coincides well with the present study 10.
 
 
                 
              Summary & 
     Conclusion
SUMMARY
• 250 clinically suspected cases of dengue were included in the study.
• Rapid dengue duo cassette method, IgM ELISA , IgG ELISA and Single-step nested RT-
PCR tests were done for the suspected fever cases.
• Incidence of dengue among fever patients in this study was 0.88%. 
• The common age group of patients  presenting with dengue was 21-40 years.
• Preponderance  of  dengue  was  found  in  males  (42.85%)  as  compared  to  females 
(29.77%).
• Fever was the most common presenting symptom (100%), followed by myalgia/arthralgia 
(71.1%),  headache  (48.88%),  haemorrhagic  manifestations  (38.88%),  rash  (27.77%), 
gastro-intestinal  symptoms  (22.22%),  hepatomegaly  (16.66%)  and  retro-orbital  pain 
(13.33%).
• The common haemorrhagic manifestations among dengue patients were gum bleeding 
and petechiae.
• Increased incidence of dengue was found during August  to December months, during 
monsoon and post monsoon period.
• Thromboctyopenia was seen in all the dengue cases and most of the cases had a platelet 
count of 50,000 to 1 lakh/cu.mm.
• Out  of  250  samples  tested,  30  patients  (66.66%)  were  found  to  be  positive  for  IgM 
antibodies in the early febrile period as compared to IgG antibodies (6.66%).
• During  the  late  febrile  period,  both  IgM and  IgG antibody positivity  was  found  to  be 
increasing (68.96%).
• Dengue  cases  were  categorized  according  to  WHO criteria  into  dengue  fever  (50%), 
dengue haemorrhagic fever (42.22%) and dengue shock syndrome(7.7%).
• Haemorrhagic manifestations (38.88%) were seen more in dengue haemorrhagic fever 
cases, with thrombocytopenia of < 50,000 platelets/cu.mm .
• Rapid  duo  cassette  method  for  dengue  showed  a  higher  case  detection  than  ELISA 
methods.
• Dengue serotype 1 was detected in one case by Single-step nested RT-PCR in the early 
febrile period.
• The proportion of secondary dengue infection was more than primary dengue infection.
• Case fatality rate was found to be 2.2% in this study.
CONCLUSION
• The incidence of dengue was 0.88% among patients attending the fever clinic and patients 
admitted with fever in Government General Hospital, Chennai.
• The seropositivity of dengue cases was 36%.
• The dengue cases were classified according to WHO guidelines and were found to be 
50% of Dengue fever cases, 42.22% of Dengue haemorrhagic fever cases and 7.7% 
of Dengue shock syndrome  cases.
• The proportion of primary dengue infections (28.88%) to secondary infections (71.11%) 
was 1:2.5.
• The serotype of dengue virus isolated in the present study belonged to  Dengue virus 
serotype-1.
• Serum samples should be collected at a very early period (1-3 days) within onset of fever 
to determine the dengue serotype by Single-Step Nested RT- PCR.
• Serological diagnosis should be done in all clinically suspected dengue cases for early 
initiation of treatment and thereby to minimize the mortality.
      Annexure
APPENDICES
   1.  IgM ELISA
       Antigen preparation
                        Antigen is supplied in liquid form, 
                        constituents per strip:
        Antigen                          2µl
                             Antigen diluent           500µl
                             Tracer(Conjugate)     502µl
        Total                        1004µl
                  Wash buffer 
Constituents per strip:
        Wash buffer concentrate       2.5ml
        Distilled water                      47.5ml     
                                                                            50 ml  
2. IgG ELISA
     Antigen preparation
          Antigen supplied in lyophilized form 
          Constituents per strip:
          Reconstituted antigen       500µl
                               Mab Tracer                       500µl
                                                                      1000µl  
   
  3. PCR BUFFERS
       TAE BUFFER
                  Constituents :
          Tris base                        54g
                        Boric acid                  27.5ml
                               EDTP(0.5M)                  20ml
                                    pH                       8.0
                 1X PCR Buffer 
Constituents:            
                    Magnesium chloride (MgCl2) 1.5mM   
                    Tris-Hydrochloride (HCl)                  50mM
                            Potassium chloride(KCl)                   75mM           
                                   pH             8.3
PROFORMA
                   Laboratory Investigation Form for Dengue Infection
Hospital:……………………………………Reg.no……………
Name  of the patient:…………….Age:……….Sex:…………
Date of  Admission:……………........   Date of Onset:……..
Suspected  Diagnosis:………………………………………..
Clinical Findings:
1. Fever Duration……………..Days………………………….
2. Petechiae………….Epistaxis………….Malena..............
3. Bleeding  time:……………
4. Clotting time:……………...
5. Platelet Count……………..
Specimen No:……………………………………………………
Date of Collection:………………………………………………
Result of Serology:……………………………………………...
 
          ABBREVIATIONS 
BHK21            -Hamster kidney cells
DENV             -Dengue virus
DF                  -Dengue Fever
DHF               -Dengue haemorrhagic fever
dNTP             -Deoxynucleotide Triphosphate
DSP               -Dengue Structural protein
DSS               -Dengue Shock Syndrome
ELISA            -Enzyme linked immunosorbent assay
LLCMK2        - Rhesus monkey kidney cells
Mab               -Monoclonal antibody
MAC-ELISA   -IgM antibody capture Elisa
NASBA          - Nucleic acid sequence-based analysis
PBS               - Phosphate Buffered Saline 
RNA               - Ribonucleic acid
rpm                - revolutions per minute
RT-PCR        - Reverse – Transcriptase Polymerase Chain Reaction
Vero              - African green monkey kidney cells
WHO             - World Health Organisation
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